v3.26.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2024
Operating expenses:      
Research and development $ (1,809,044) $ (2,254,244) $ (8,243,571)
Operating Expenses (6,690,509) (4,837,653) (7,506,161)
Total operating expenses (8,499,553) (7,091,897) (15,749,732)
Other income/(expense):      
Finance expense (net) (442,117) (878,174) (1,053,313)
Loss from operations before income taxes (8,941,670) (7,970,071) (16,803,045)
Income tax (7,987) 3,263,779 (22,416)
Loss for the year (8,949,657) (4,706,292) (16,825,461)
Other Comprehensive loss:      
Exchange differences on translating foreign operations (659,139) (158,973) 141,095
Comprehensive loss $ (9,608,796) $ (4,865,265) $ (16,684,366)
Basic loss per share attributable to common shareholders $ (0.24) $ (0.12) $ (0.57)
Diluted loss per share attributable to common shareholders $ (0.24) $ (0.12) $ (0.57)